CN Stock MarketDetailed Quotes

300966 Hubei Goto Biopharm

Watchlist
  • 16.65
  • +0.35+2.15%
Market Closed Dec 27 15:00 CST
1.92BMarket Cap-137.60P/E (TTM)

Hubei Goto Biopharm Key Stats

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
Total operating revenue
-5.10%365.39M
-12.69%233.82M
2.35%122.23M
-6.31%566.4M
-13.83%385.04M
-0.20%267.82M
-0.85%119.42M
2.32%604.57M
0.20%446.82M
-11.34%268.35M
Operating revenue
-5.10%365.39M
-12.69%233.82M
2.35%122.23M
-6.31%566.4M
-13.83%385.04M
-0.20%267.82M
-0.85%119.42M
2.32%604.57M
0.20%446.82M
-11.34%268.35M
Other operating revenue
----
-1.41%257.99K
----
433.77%897.49K
----
148.91%261.69K
----
-93.32%168.14K
----
-94.97%105.13K
Total operating cost
9.36%407.87M
-2.75%250.3M
1.85%122.39M
-4.22%542.21M
-8.30%372.95M
6.68%257.38M
10.38%120.17M
7.15%566.09M
3.85%406.72M
-7.31%241.26M
Operating cost
5.75%313.41M
-7.16%193.18M
0.51%95.87M
-5.38%441.28M
-13.20%296.36M
4.33%208.07M
8.40%95.38M
7.21%466.35M
3.74%341.44M
-10.05%199.44M
Operating tax surcharges
-6.56%717.44K
6.20%578.94K
-33.39%239.98K
45.48%1M
60.27%767.81K
174.12%545.11K
454.95%360.31K
-55.12%688.31K
-66.24%479.08K
-80.39%198.86K
Operating expense
28.12%4.68M
1.90%2.47M
-0.39%864.91K
43.97%7.06M
41.47%3.65M
31.50%2.42M
-3.59%868.26K
-10.31%4.91M
-18.54%2.58M
-19.12%1.84M
Administration expense
24.52%43.36M
27.13%26.68M
28.38%13.03M
14.33%44.4M
27.19%34.82M
20.15%20.98M
28.64%10.15M
-11.61%38.83M
-2.99%27.38M
-5.03%17.46M
Financial expense
91.35%13.47M
64.87%7.12M
0.59%2.89M
2.05%10.37M
32.55%7.04M
-19.20%4.32M
-8.49%2.87M
92.68%10.16M
2.26%5.31M
30.10%5.34M
-Interest expense (Financial expense)
38.52%13.85M
18.32%8.4M
-12.04%3.36M
-1.43%13.18M
9.71%10M
5.68%7.1M
16.10%3.82M
158.44%13.37M
72.95%9.11M
70.24%6.72M
-Interest Income (Financial expense)
60.88%-763.78K
63.67%-576.73K
60.50%-360.14K
-10.89%-2.13M
-14.59%-1.95M
-62.52%-1.59M
-99.30%-911.69K
-61.57%-1.92M
-117.50%-1.7M
-222.70%-976.86K
Research and development
6.33%32.23M
-3.60%20.28M
-9.87%9.51M
-15.61%38.1M
2.66%30.32M
23.97%21.04M
18.60%10.55M
21.61%45.15M
20.47%29.53M
32.89%16.97M
Credit Impairment Loss
302.87%1.48M
-45.91%-1.34M
235.63%771.67K
-1.57%-4.57M
71.71%-731.09K
56.24%-919.63K
42.09%-568.94K
-685.39%-4.5M
24.02%-2.58M
-198.65%-2.1M
Asset Impairment Loss
1,567.21%6.73M
1,005.79%4.16M
---414.96K
-1,031.90%-7.71M
-117.28%-458.72K
-117.28%-458.72K
----
129.24%827.12K
720.54%2.66M
895.71%2.66M
Other net revenue
407.64%15.24M
1,040.07%6.32M
1,096.51%2.4M
-1,207.50%-4.66M
98.73%3M
-70.87%554.35K
-109.91%-240.49K
205.88%420.7K
194.90%1.51M
221.75%1.9M
Fair value change income
100.00%0.05
100.00%0.05
100.00%0.05
-199.91%-11.87K
---11.88K
---11.88K
-1,658.72%-8.24K
826.08%11.88K
----
----
Invest income
668.80%382.37K
661.70%253.99K
-222.44%-113.76K
232.79%258.34K
60.81%-67.22K
175.80%33.35K
4,625.13%92.91K
81.49%-194.55K
82.92%-171.52K
95.09%-43.99K
-Including: Investment income associates
286.62%318.05K
463.56%253.99K
-252.66%-113.76K
1,580.11%154.88K
---170.43K
-250.44%-69.86K
306.32%74.52K
-87.11%9.22K
----
--46.44K
Asset deal income
-234.78%-226.82K
--27.18K
----
2,788.53%168.3K
2,515.35%168.3K
--0
----
---6.26K
---6.97K
---11.88K
Other revenue
67.45%6.87M
68.77%3.23M
783.43%2.15M
68.18%7.21M
153.47%4.1M
36.02%1.91M
-50.09%243.78K
-6.61%4.29M
-50.07%1.62M
278.71%1.41M
Operating profit
-280.57%-27.24M
-192.40%-10.16M
326.02%2.24M
-49.80%19.53M
-63.75%15.09M
-62.08%10.99M
-107.06%-988.98K
-37.96%38.9M
-21.05%41.61M
-29.00%28.99M
Add:Non operating Income
-18.53%2.83M
-78.39%730.46K
-96.57%149.53K
103.25%1.92M
22.45%3.48M
1,069.48%3.38M
9,471.78%4.36M
-95.98%944.29K
-63.83%2.84M
-96.08%289.03K
Less:Non operating expense
83,267.48%1.92M
1,929,384.74%1.91M
807,042.16%449.09K
74.87%2.33M
-98.71%2.31K
-98.72%99.23
98.50%55.64
1,234.37%1.33M
112.09%178.01K
-96.25%7.75K
Total profit
-241.85%-26.33M
-178.91%-11.34M
-42.66%1.94M
-50.37%19.12M
-58.08%18.56M
-50.89%14.37M
-75.97%3.38M
-55.28%38.51M
-26.79%44.28M
-39.01%29.27M
Less:Income tax cost
-248.05%-9.8M
-97.38%-4.46M
-247.59%-957.39K
-117.41%-2.17M
-157.51%-2.82M
-186.75%-2.26M
-121.61%-275.44K
-112.42%-999.75K
-26.36%4.9M
-63.59%2.6M
Net profit
-177.32%-16.53M
-141.41%-6.89M
-20.76%2.89M
-46.12%21.29M
-45.72%21.38M
-37.64%16.63M
-71.42%3.65M
-49.38%39.51M
-26.84%39.38M
-34.71%26.67M
Net profit from continuing operation
-177.32%-16.53M
-141.41%-6.89M
-20.76%2.89M
-46.12%21.29M
-45.72%21.38M
-37.64%16.63M
-71.42%3.65M
-49.38%39.51M
-26.84%39.38M
-34.71%26.67M
Less:Minority Profit
-68.04%-2.37M
-110.53%-1.77M
-75.26%-654.22K
-147.96%-1.72M
-162.30%-1.41M
-169.49%-839.93K
-39.29%-373.28K
-161.26%-691.72K
-124.81%-536.73K
-56.91%-311.67K
Net profit of parent company owners
-162.16%-14.16M
-129.30%-5.12M
-11.86%3.55M
-42.78%23.01M
-42.92%22.78M
-35.24%17.47M
-69.15%4.02M
-48.67%40.21M
-26.17%39.92M
-34.26%26.98M
Earning per share
Basic earning per share
-160.00%-0.12
-126.67%-0.04
0.00%0.03
-42.86%0.2
-42.86%0.2
-35.92%0.15
-72.73%0.03
-52.81%0.35
-33.96%0.35
-45.56%0.2341
Diluted earning per share
-160.00%-0.12
-126.67%-0.04
0.00%0.03
-42.86%0.2
-42.86%0.2
-32.34%0.15
-72.73%0.03
-52.81%0.35
-33.96%0.35
-48.44%0.2217
Other composite income
Total composite income
-177.32%-16.53M
-141.41%-6.89M
-20.76%2.89M
-46.12%21.29M
-45.72%21.38M
-37.64%16.63M
-71.42%3.65M
-49.38%39.51M
-26.84%39.38M
-34.71%26.67M
Total composite income of parent company owners
-162.16%-14.16M
-129.30%-5.12M
-11.86%3.55M
-42.78%23.01M
-42.92%22.78M
-35.24%17.47M
-69.15%4.02M
-48.67%40.21M
-26.17%39.92M
-34.26%26.98M
Total composite income of minority owners
-68.04%-2.37M
-110.53%-1.77M
-75.26%-654.22K
-147.96%-1.72M
-162.30%-1.41M
-169.49%-839.93K
-39.29%-373.28K
-161.26%-691.72K
-124.81%-536.73K
-56.91%-311.67K
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
--
--
--
Unqualified opinion
--
--
--
Unqualified opinion
--
--
Auditor
--
--
--
Daxin Certified Public Accountants (Special General Partnership)
--
--
--
Daxin Certified Public Accountants (Special General Partnership)
--
--
(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022
Total operating revenue -5.10%365.39M-12.69%233.82M2.35%122.23M-6.31%566.4M-13.83%385.04M-0.20%267.82M-0.85%119.42M2.32%604.57M0.20%446.82M-11.34%268.35M
Operating revenue -5.10%365.39M-12.69%233.82M2.35%122.23M-6.31%566.4M-13.83%385.04M-0.20%267.82M-0.85%119.42M2.32%604.57M0.20%446.82M-11.34%268.35M
Other operating revenue -----1.41%257.99K----433.77%897.49K----148.91%261.69K-----93.32%168.14K-----94.97%105.13K
Total operating cost 9.36%407.87M-2.75%250.3M1.85%122.39M-4.22%542.21M-8.30%372.95M6.68%257.38M10.38%120.17M7.15%566.09M3.85%406.72M-7.31%241.26M
Operating cost 5.75%313.41M-7.16%193.18M0.51%95.87M-5.38%441.28M-13.20%296.36M4.33%208.07M8.40%95.38M7.21%466.35M3.74%341.44M-10.05%199.44M
Operating tax surcharges -6.56%717.44K6.20%578.94K-33.39%239.98K45.48%1M60.27%767.81K174.12%545.11K454.95%360.31K-55.12%688.31K-66.24%479.08K-80.39%198.86K
Operating expense 28.12%4.68M1.90%2.47M-0.39%864.91K43.97%7.06M41.47%3.65M31.50%2.42M-3.59%868.26K-10.31%4.91M-18.54%2.58M-19.12%1.84M
Administration expense 24.52%43.36M27.13%26.68M28.38%13.03M14.33%44.4M27.19%34.82M20.15%20.98M28.64%10.15M-11.61%38.83M-2.99%27.38M-5.03%17.46M
Financial expense 91.35%13.47M64.87%7.12M0.59%2.89M2.05%10.37M32.55%7.04M-19.20%4.32M-8.49%2.87M92.68%10.16M2.26%5.31M30.10%5.34M
-Interest expense (Financial expense) 38.52%13.85M18.32%8.4M-12.04%3.36M-1.43%13.18M9.71%10M5.68%7.1M16.10%3.82M158.44%13.37M72.95%9.11M70.24%6.72M
-Interest Income (Financial expense) 60.88%-763.78K63.67%-576.73K60.50%-360.14K-10.89%-2.13M-14.59%-1.95M-62.52%-1.59M-99.30%-911.69K-61.57%-1.92M-117.50%-1.7M-222.70%-976.86K
Research and development 6.33%32.23M-3.60%20.28M-9.87%9.51M-15.61%38.1M2.66%30.32M23.97%21.04M18.60%10.55M21.61%45.15M20.47%29.53M32.89%16.97M
Credit Impairment Loss 302.87%1.48M-45.91%-1.34M235.63%771.67K-1.57%-4.57M71.71%-731.09K56.24%-919.63K42.09%-568.94K-685.39%-4.5M24.02%-2.58M-198.65%-2.1M
Asset Impairment Loss 1,567.21%6.73M1,005.79%4.16M---414.96K-1,031.90%-7.71M-117.28%-458.72K-117.28%-458.72K----129.24%827.12K720.54%2.66M895.71%2.66M
Other net revenue 407.64%15.24M1,040.07%6.32M1,096.51%2.4M-1,207.50%-4.66M98.73%3M-70.87%554.35K-109.91%-240.49K205.88%420.7K194.90%1.51M221.75%1.9M
Fair value change income 100.00%0.05100.00%0.05100.00%0.05-199.91%-11.87K---11.88K---11.88K-1,658.72%-8.24K826.08%11.88K--------
Invest income 668.80%382.37K661.70%253.99K-222.44%-113.76K232.79%258.34K60.81%-67.22K175.80%33.35K4,625.13%92.91K81.49%-194.55K82.92%-171.52K95.09%-43.99K
-Including: Investment income associates 286.62%318.05K463.56%253.99K-252.66%-113.76K1,580.11%154.88K---170.43K-250.44%-69.86K306.32%74.52K-87.11%9.22K------46.44K
Asset deal income -234.78%-226.82K--27.18K----2,788.53%168.3K2,515.35%168.3K--0-------6.26K---6.97K---11.88K
Other revenue 67.45%6.87M68.77%3.23M783.43%2.15M68.18%7.21M153.47%4.1M36.02%1.91M-50.09%243.78K-6.61%4.29M-50.07%1.62M278.71%1.41M
Operating profit -280.57%-27.24M-192.40%-10.16M326.02%2.24M-49.80%19.53M-63.75%15.09M-62.08%10.99M-107.06%-988.98K-37.96%38.9M-21.05%41.61M-29.00%28.99M
Add:Non operating Income -18.53%2.83M-78.39%730.46K-96.57%149.53K103.25%1.92M22.45%3.48M1,069.48%3.38M9,471.78%4.36M-95.98%944.29K-63.83%2.84M-96.08%289.03K
Less:Non operating expense 83,267.48%1.92M1,929,384.74%1.91M807,042.16%449.09K74.87%2.33M-98.71%2.31K-98.72%99.2398.50%55.641,234.37%1.33M112.09%178.01K-96.25%7.75K
Total profit -241.85%-26.33M-178.91%-11.34M-42.66%1.94M-50.37%19.12M-58.08%18.56M-50.89%14.37M-75.97%3.38M-55.28%38.51M-26.79%44.28M-39.01%29.27M
Less:Income tax cost -248.05%-9.8M-97.38%-4.46M-247.59%-957.39K-117.41%-2.17M-157.51%-2.82M-186.75%-2.26M-121.61%-275.44K-112.42%-999.75K-26.36%4.9M-63.59%2.6M
Net profit -177.32%-16.53M-141.41%-6.89M-20.76%2.89M-46.12%21.29M-45.72%21.38M-37.64%16.63M-71.42%3.65M-49.38%39.51M-26.84%39.38M-34.71%26.67M
Net profit from continuing operation -177.32%-16.53M-141.41%-6.89M-20.76%2.89M-46.12%21.29M-45.72%21.38M-37.64%16.63M-71.42%3.65M-49.38%39.51M-26.84%39.38M-34.71%26.67M
Less:Minority Profit -68.04%-2.37M-110.53%-1.77M-75.26%-654.22K-147.96%-1.72M-162.30%-1.41M-169.49%-839.93K-39.29%-373.28K-161.26%-691.72K-124.81%-536.73K-56.91%-311.67K
Net profit of parent company owners -162.16%-14.16M-129.30%-5.12M-11.86%3.55M-42.78%23.01M-42.92%22.78M-35.24%17.47M-69.15%4.02M-48.67%40.21M-26.17%39.92M-34.26%26.98M
Earning per share
Basic earning per share -160.00%-0.12-126.67%-0.040.00%0.03-42.86%0.2-42.86%0.2-35.92%0.15-72.73%0.03-52.81%0.35-33.96%0.35-45.56%0.2341
Diluted earning per share -160.00%-0.12-126.67%-0.040.00%0.03-42.86%0.2-42.86%0.2-32.34%0.15-72.73%0.03-52.81%0.35-33.96%0.35-48.44%0.2217
Other composite income
Total composite income -177.32%-16.53M-141.41%-6.89M-20.76%2.89M-46.12%21.29M-45.72%21.38M-37.64%16.63M-71.42%3.65M-49.38%39.51M-26.84%39.38M-34.71%26.67M
Total composite income of parent company owners -162.16%-14.16M-129.30%-5.12M-11.86%3.55M-42.78%23.01M-42.92%22.78M-35.24%17.47M-69.15%4.02M-48.67%40.21M-26.17%39.92M-34.26%26.98M
Total composite income of minority owners -68.04%-2.37M-110.53%-1.77M-75.26%-654.22K-147.96%-1.72M-162.30%-1.41M-169.49%-839.93K-39.29%-373.28K-161.26%-691.72K-124.81%-536.73K-56.91%-311.67K
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions ------Unqualified opinion------Unqualified opinion----
Auditor ------Daxin Certified Public Accountants (Special General Partnership)------Daxin Certified Public Accountants (Special General Partnership)----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.